ZYBTHealthcare · Drug Manufacturers - Specialty & GenericZYBT Stock Forecast: Zhengye Biotechnology Holding Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 43 of 100 as at 1 Aug 2026 — in the lower half.
ZYBT stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Zhengye Biotechnology Holding Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (16): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Zhengye Biotechnology Holding Ltd. — and when they’d sell — is the membership.
ZYBT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ZYBT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZYBT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Zhengye Biotechnology Holding Ltd. (ZYBT) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 63.3×
- Price / sales
- 0.5×
- Price / book
- 1.5×
- EV / EBITDA
- −3.2×
Cheaper than 12% of US stocks
Cheaper than 82% of US stocks
Cheaper than 57% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- −40.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −77.0%
- Net margin
- −60.0%
Higher than 6% of US stocks
Higher than 15% of US stocks
Higher than 9% of US stocks
- Return on equity
- −25.2%
- Return on assets
- −9.5%
- Dividend yield
- —
Higher than 29% of US stocks
Higher than 27% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ZYBT vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZYBT appears on the weeks it earns a place.
Frequently asked questions about ZYBT stock
How does Ticker Nerd's model rank ZYBT?
As at 1 Aug 2026, Zhengye Biotechnology Holding Ltd. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).
What is the ZYBT stock forecast for 2030?
No analyst covering Zhengye Biotechnology Holding Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZYBT are extrapolating price history, which says nothing about the business.
How has ZYBT stock performed over the past year?
Zhengye Biotechnology Holding Ltd. returned -74.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Zhengye Biotechnology Holding Ltd. do?
Zhengye Biotechnology Holdings Inc. is a veterinary biopharmaceutical company specializing in the research, development, manufacturing and sale of animal vaccines in China.
About Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holdings Inc. is a veterinary biopharmaceutical company specializing in the research, development, manufacturing and sale of animal vaccines in China. The firm focuses on vaccines for livestock, providing immunization products for swine, cattle, goats, sheep, poultry and other farm animals, as well as selected vaccines for household pets such as dogs. Its portfolio includes monovalent, polyvalent, combined, and combined polyvalent formulations designed to address a wide range of infectious diseases in commercial animal husbandry. Zhengye Biotechnology Holdings Inc. serves agricultural producers and animal health providers across multiple provincial regions in China and exports vaccines to international markets including Vietnam, Pakistan and Egypt. Operating through its main entity in Jilin, China, the company plays a role in supporting animal health and contributing to food safety within the broader healthcare and pharmaceutical preparations industry.
269 employees · China · https://www.jlzybio.com